Alaunos Therapeutics Reports Executive Changes & Compensation on Dec 29

TL;DR

**Alaunos Therapeutics just reported executive changes and compensation arrangements, signaling potential shifts.**

AI Summary

Alaunos Therapeutics, Inc. filed an 8-K on January 2, 2024, reporting an event that occurred on December 29, 2023. The filing indicates a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Regulation FD Disclosure'. This matters to investors because changes in leadership and executive compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting the stock's value.

Why It Matters

Changes in executive leadership and compensation can significantly influence a company's strategic direction and operational stability, directly affecting investor confidence and stock performance.

Risk Assessment

Risk Level: medium — Changes in executive leadership can introduce uncertainty regarding future company direction and stability, posing a medium risk to investors.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific details regarding the executive changes and compensation arrangements to understand their potential impact on the company's future strategy and performance.

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — the registrant filing the 8-K
• December 29, 2023 (date) — date of the earliest event reported in the 8-K
• January 2, 2024 (date) — date the 8-K was filed
• 001-33038 (other) — Commission File Number for Alaunos Therapeutics, Inc.
• TCRT (other) — Trading Symbol for Alaunos Therapeutics, Inc. Common Stock

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar
• $50,000 — receives a base annual cash retainer of $50,000. In addition, Mr. Hogue will be granted

Filing Documents

• d682377d8k.htm (8-K) — 29KB
• 0001193125-24-000240.txt ( ) — 151KB
• tcrt-20231229.xsd (EX-101.SCH) — 3KB
• tcrt-20231229_lab.xml (EX-101.LAB) — 18KB
• tcrt-20231229_pre.xml (EX-101.PRE) — 11KB
• d682377d8k_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Corporate Update As a result of previously announced efforts to reduce spend and implement cost-saving measures, as of the date of this report, the Company anticipates its cash resources will be sufficient to fund its operations into the third quarter of 2024. The Company is taking steps to implement the reverse stock split previously approved by its stockholders at its annual meeting held on June 6, 2023. No assurances can be made that the Company will successfully implement the reverse stock split or that, if implemented, it will increase the price of the Company's stock or cure the previously disclosed Nasdaq deficiencies. The information contained in this Item 7.01 is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this Form 8-K include, without limitation, statements regarding the Company's anticipated cash runway, whether the Company will effect a reverse stock split and the impact or benefits of any reverse stock split. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties, and actual results may differ materially from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, without limitation, the potential delisting of the Company's common stock from Nasdaq, which may adversely impact trading in the Company's common stock and the Company's ability to raise financing; the Company's historical and expected continuing significant losses; the Company's need for additional funding, which may not be available on reasonable terms or at all; and the other important factors described under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the SEC on November 14, 2023, and its other filings with the SEC. Any forward-looking statement made by the Company in this Current Report Form 8-K is based only o

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alaunos Therapeutics, Inc. Date. January 2, 2024 By: /s/ Michael Wong Name: Michael Wong Title: Vice President, Finance

View Full Filing

View this 8-K filing on SEC EDGAR